

[For Immediate Release]



Biostime International Holdings Limited
合生元國際控股有限公司

**Senior Notes Issue and Term Loan Facility
To Enhance Capital Efficiency and Optimize Capital Structure**

(Hong Kong, 16 June 2016) **Biostime International Holdings Limited** ("Biostime" or the "Company", together with its subsidiaries, the "Group"; stock code: 1112), a leading premium family nutrition and care products provider, is pleased to announce that the Group has successfully issued US\$400 million 7.25% senior notes due 2021 (the "Senior Notes") with Goldman Sachs as the exclusive book runner. The proceeds of these Senior Notes will be used exclusively to repurchase the convertible bonds due 2019.

After the US\$450 million three-year term loan facility secured in April this year (the "Term Loan Facility"), this Senior Notes issue enables the Group to successfully complete its refinancing, therefore enhancing its capital efficiency and further optimizing its capital structure.

The Group received its first-time corporate ratings of BB with positive outlook from Standard and Poor's and Ba2 with stable outlook from Moody's. The ratings of the Senior Notes are one notch down given its subordination to the Term Loan Facility.

Mr. Jason Wang, Chief Financial Officer of the Group said, "This Senior Notes issue, together with the Term Loan Facility secured in April 2016, will help the Group enhance its capital efficiency, optimize its capital structure further and foster better financial stability with positive deleveraging outlook."

Timeline for Biostime's financing and capital structure optimization efforts

Date	Event
Feb 2014	– Issuance of HK\$3.1 billion zero-coupon convertible bonds maturing in Feb 2019 (the "Convertible Bonds")
Sep 2015	– Secured a US\$450 million bridge term loan facility in relation to an acquisition into a 83% equity interest in Swisse Wellness (the "Bridge Financing")
Apr 2016	– Secured a US\$450 million three-year senior secured term loan facility to refinance the Bridge Financing
Jun 2016	– Issuance of US\$400 million 7.25% Senior Notes due 2021 to repurchase the Convertible Bonds

– End –

About Biostime

Biostime is a premium family nutrition and care products provider. The company's family of products includes premium probiotic supplements for children, infant formulas and dried baby food products, baby care products in China. It also owns 83% equity interest in Swisse Wellness Group Pty Ltd., which is a leading provider of vitamins, herbal, mineral supplements products in Australia. The shares of Biostime have been listed on the Hong Kong Stock Exchange since 2010.

For further inquiries, please contact:

iPR Ogilvy & Mather

Natalie Tam / Lorraine Luk / Andrea Leung / Hazel Chan / Lokyi Chan

Tel: (852) 2136 6182 / 2169 0467 / 3920 7683 / 3920 7651 / 3920 7656

Fax: (852) 3170 6606

Email: biostime@iprogilvy.com